| Symbol | RZLT |
|---|---|
| Name | REZOLUTE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 201 REDWOOD SHORES PARKWAY,SUITE 315, REDWOOD CITY, California, 94065, United States |
| Telephone | +1 650 206-4507 |
| Fax | — |
| — | |
| Website | https://www.rezolutebio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001509261 |
| Description | Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402. Additional info from NASDAQ: |
ROBERTS BRIAN KENNETH 🔴 sold 3.1K shares of Rezolute, Inc. (RZLT) at $4.99 Transaction Date: Jul 02, 2026 | Filing ID: 000936
Read moreElam Nevan C 🔴 sold 8.0K shares of Rezolute, Inc. (RZLT) at $4.99 Transaction Date: Jul 02, 2026 | Filing ID: 000930
Read moreEvans Daron 🔴 sold 3.1K shares of Rezolute, Inc. (RZLT) at $4.99 Transaction Date: Jul 02, 2026 | Filing ID: 000929
Read moreRezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Read moreRezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Read moreRezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Read more(70% Positive) REZOLUTE, INC. (RZLT) Announces Enrollment Update for expected Due to Patient Enrollment Issues, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreRezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Read moreNew Form SCHEDULE 13G - Rezolute, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001193125-26-225186 <b>Size:</b> 133 KB
Read more(75% Positive) REZOLUTE, INC. (RZLT) Announces Enrollment Update for update Due to Patient Enrollment Issues, Manufacturing Considerations, Efficacy Assessment
Read more